Maintenance therapy with the <i>FMS</i>‐like tyrosine kinase 3 inhibitor gilteritinib in patients with <i>FMS</i>‐like tyrosine kinase 3–internal tandem duplication acute myeloid leukemia: A phase 2 study
The primary end point was not achieved; however, an observed trend toward potential benefit was noted in patients with FLT3-ITD AML who had not undergone prior HSCT.
Authors
- Richard Kelly (ORCID: https://orcid.org/0000-0002-0622-5644)
- Martin Jädersten (ORCID: https://orcid.org/0000-0001-5217-3235)
- Nahla Hasabou
- Caroline Chen (ORCID: https://orcid.org/0009-0002-9471-0822)
- David Delgado‐Gómez (ORCID: https://orcid.org/0000-0002-2976-2602)
- Alessandro Rambaldi (ORCID: https://orcid.org/0000-0002-3739-7502)
- Jason E. Hill (ORCID: https://orcid.org/0000-0003-2512-1661)
- Wensheng He (ORCID: https://orcid.org/0000-0002-4893-1344)
- Stanley C. Gill (ORCID: https://orcid.org/0009-0001-0063-8755)
- Gunnar Juliusson (ORCID: https://orcid.org/0000-0002-9457-5272)
- Emmanuel Gyan (ORCID: https://orcid.org/0000-0002-7651-9189)
- László Szerafin (ORCID: https://orcid.org/0000-0001-9534-3230)
- Mark D. Minden
- Kohmei Kubo
Institutions
- Karolinska University Hospital (SE)
- Inserm (FR)
- St James's University Hospital (GB)
- Princess Margaret Cancer Centre (CA)
- Karolinska Institutet (SE)
- Aomori Prefectural Central Hospital (JP)
- Centre Hospitalier Universitaire de Tours (FR)
- Clinical Investigation Center Plurithematic Tours (FR)
- Ospedale Papa Giovanni XXIII (IT)
- Skåne University Hospital (SE)
- Astellas Pharma (United States) (US)
Publication Details
- Journal
- Cancer
- Published
- 2025-02-13
- DOI
- https://doi.org/10.1002/cncr.35746
- Citations
- 3
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 5.31
Funders
- Astellas Pharma